MedTrace Logo

N-Acetyl-Cysteine for Treatment of AGA in Men

NCT04209803 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-08-27

No results posted yet for this study

Summary

To study the effectiveness and safety of the reactive oxygen species scavenger N-acetyl-cysteine (NAC) as a single therapy and in combination with the topically applied minoxidil for the treatment of the early-onset androgenetic alopecia in men.

Conditions

Interventions

DRUG

Minoxidil 5% topically and oral NAC 600 mg

Topical 5% Minoxidil and N-Acetyl-Cysteine 600 mg orally

Sponsors & Collaborators

  • Ain Shams University

    collaborator OTHER

  • Kafrelsheikh University

    lead OTHER

Principal Investigators

  • Mahira H El Sayed, Professor · Ain Shams University- Faculty of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-01
Primary Completion
2020-09-02
Completion
2020-10-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04209803 on ClinicalTrials.gov